Wellsim Biomedical Technologies Inc is usefully understood as having developed a liquid biopsy biotechnology intended for non-invasive cancer testing. The company's capabilities address conduct of the biopsy through precise stabilization, enrichment, isolation -- analytical interrogation of circulating extracellular vesicles and exosomes from cell-free specimens such as urine, saliva, and plasma, enabling healthcare professionals to perform therapeutic and clinical diagnostics.
